<DOC>
	<DOC>NCT01192191</DOC>
	<brief_summary>The primary purpose of the study is to evaluate the safety and tolerability of fluticasone furoate/GW642444 inhalation powder when administered once-daily for 52 weeks in Japanese patients with COPD.</brief_summary>
	<brief_title>A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Out patient at least 40 years of age Both genders; females childbearing potencial must be willing to use birth control method A diagnosis of COPD at Screening Subjects with a current or prior history of at least 10 packyears of cigarett smoking at Screening Postbronchodilator FEV1/FVC ratio of less than 70% Postbronchodilator FEV1 of less than 80% Current diagnosis of sthma Respiratory disorders other than COPD Upper or lower respiratory infection, or exacerbation of COPD within 4 weeka prior to Screening Concurrent other disease that would confound study participation or affect subject safety Allergies to study drugs, study drugs' excipients, medications related to study drugs Taking another investigational medication or medication prohibited for use during this study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>GW642444</keyword>
	<keyword>COPD</keyword>
	<keyword>Fluticasone Furoate</keyword>
</DOC>